Home › Calculator › IPSEY Dividend Calculator 2026
IPSEY DRIP Calculator & Dividend Yield 2026
1.05% YieldHealthcareIpsen S.A. · OTC
Price: $43.85 · Annual div: $0.4614/share · Frequency: annual · Payout ratio: 36% · Ex-div: 2026-06-04
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When IPSEY pays your bills
Year your monthly dividend income covers each expense (based on current settings)
IPSEY Dividend History — Last 16 Payments
| Ex-Dividend Date | Payment Date | Amount / Share | TTM Yield | Stock Price |
|---|---|---|---|---|
| 2026-06-04Latest | 2026-06-22 | $0.4614 | 1.94% | $44.46 |
| 2025-06-09 | 2025-06-25 | $0.3991 | 1.33% | $30.11 |
| 2024-05-31 | 2024-06-14 | $0.3265 | 2.16% | $30.06 |
| 2023-06-02 | 2023-06-21 | $0.3240 | 1.08% | $29.98 |
| 2022-05-31 | 2022-06-09 | $0.3150 | 1.24% | $25.50 |
| 2021-05-28 | 2021-06-09 | $0.3050 | 2.40% | $24.00 |
| 2020-06-03 | 2020-06-12 | $0.2710 | — | — |
| 2019-05-31 | 2019-06-20 | $0.2790 | — | — |
| 2018-06-04 | 2018-06-21 | $0.3070 | — | — |
| 2017-06-08 | 2017-07-11 | $0.2340 | — | — |
| 2016-05-31 | 2016-07-13 | $0.2380 | — | — |
| 2015-05-26 | 2015-07-06 | $0.2380 | — | — |
| 2014-06-04 | 2014-07-02 | $0.2750 | — | — |
| 2013-05-31 | 2013-07-08 | $0.2617 | — | — |
| 2012-06-01 | 2012-06-18 | $0.2496 | — | — |
| 2011-05-26 | 2011-06-13 | $0.2929 | — | — |
About Ipsen S.A. (IPSEY) — Dividend Analysis 2026
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
Similar dividend stocks to IPSEY
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full IPSEY DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open IPSEY position with:
🌍 IPSEY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold IPSEY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 1.05% | -1.75% | $105 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.89% | -1.91% | $89 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.84% | -1.96% | $84 / yr |
| 🇬🇧 UK ISA | 0% | 1.05% | -1.75% | $105 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.96% | -1.84% | $96 / yr |
| 🇨🇦 TFSA | 0% | 1.05% | -1.75% | $105 / yr |
| 🇨🇦 CA Taxable | 25% | 0.79% | -2.01% | $79 / yr |
| 🇦🇺 Super (pension) | 15% | 0.89% | -1.91% | $89 / yr |
| 🇦🇺 AU Taxable | 30% | 0.73% | -2.06% | $74 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.77% | -2.03% | $77 / yr |
| 🇫🇷 FR Taxable | 30% | 0.73% | -2.06% | $74 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 IPSEY Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.46/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 IPSEY Dividend Payment Schedule
IPSEY pays annually — 1 payment per year.
📊 IPSEY vs Healthcare Benchmarks
How IPSEY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for IPSEY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ IPSEY Insider Activity
No recent SEC filings reported in the last 90 days.Peer Group
Similar companies in the same sectorCompare IPSEY with peers: IPSEY vs CHALF · IPSEY vs DSKYF · IPSEY vs DSNKY
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the IPSEY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Ipsen S.A. (IPSEY) is currently trading at $43.85, 14% below its 52-week high. The current dividend yield is 1.05% based on an annual payout of $0.4614 per share.
IPSEY (Ipsen S.A.) — 1.05% Dividend Yield Analysis
Ipsen S.A. (IPSEY) is a healthcare stock currently trading at $43.85 with a dividend yield of 1.05%. It pays an annual dividend of $0.4614 per share. The payout ratio of 36% suggests the dividend is well-covered by earnings. Over the past 5 years, IPSEY has grown its dividend at a compound annual rate of 6.0%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest IPSEY News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.
How investors use the IPSEY dividend calculator
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.